title: [Experience of application of Russian biosimilar of interferon beta-1b for treatment of pediatric multiple sclerosis].
abstract: OBJECTIVE
  To evaluate efficacy and safety of biosimilars of interferon beta-1b (Infibeta) in patients aged 14 to 17 years.
  
  
  METHODS
  Interferon beta 1b (Infibeta) was appointed 9 children and adolescents (4 boys and 5 girls) between the ages of 14 to 17 years (mean age of onset of therapy 16.22±1.09).
  
  
  RESULTS
  In the course of therapy there was a significant decrease in the annualrelapse rate (ARR) to 0.33±0.5 (from 0 to 1, r≤0,0001) and the of regression of neurological deficit on the EDSS scale up to ±1.94±0.68 (1.5 to 3, p≤0.05). No cases of cancellation was not recorded due to poor tolerability or inefficiency.
  
  
  CONCLUSIONS
  Although numerically small so far, but quite successful results on the use of Russian interferon beta-1b biosimilar (Infibeta) in children, we can recommend this treatment as sufficiently safe and effective.
authors.affiliation: Interregional of Multiple Sclerosis Departament in City Clinical Hospital #24, Moscow, Russia; Pirogov Russian National Research Medical University, Moscow, Russia.
authors.forename: E V
authors.initials: EV
authors.lastname: Popova
authors.affiliation: Interregional of Multiple Sclerosis Departament in City Clinical Hospital #24, Moscow, Russia; Pirogov Russian National Research Medical University, Moscow, Russia.
authors.forename: A N
authors.initials: AN
authors.lastname: Boyko
authors.affiliation: Research and Practical Center of Pediatric Psychoneurology, Moscow, Russia.
authors.forename: O V
authors.initials: OV
authors.lastname: Bykova
authors.affiliation: Research and Practical Center of Pediatric Psychoneurology, Moscow, Russia.
authors.forename: I G
authors.initials: IG
authors.lastname: Nankina
authors.affiliation: Research and Practical Center of Pediatric Psychoneurology, Moscow, Russia.
authors.forename: T T
authors.initials: TT
authors.lastname: Batysheva
mesh_terms: D000293:Adolescent; D059451:Biosimilar Pharmaceuticals / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006801:Humans; D000068576:Interferon beta-1b / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy*; D012426:Russia; D016896:Treatment Outcome
chemical_list: D059451:Biosimilar Pharmaceuticals; D000068576:Interferon beta-1b